Bioequivalence Study of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Oral Suspension Compared to Augmentin® Forte in Healthy Subjects Under Fed Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Amoxicillin and Clavulanic Acid 250 mg/62.5 mg/5 mL Powder for Oral Suspension compared to Augmentin® Forte 250 mg/62.5 mg/5 mL Powder for Oral Suspension in healthy participants under fed conditions. Bioequivalence studies are crucial in determining whether two pharmaceutical products are equivalent in terms of their bioavailability, which is essential for ensuring therapeutic equivalence and consistent clinical outcomes. This study does not involve any specific medical condition, as it is conducted in healthy participants to assess the pharmacokinetic properties of the formulations.

The clinical trial involves a **study population** that includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants do not have any specific medical conditions as a prerequisite for inclusion in the trial. Information regarding lifestyle considerations such as diet, physical activity, or habits has not been provided. The sponsor has not given further details on the selection process or any key inclusion or exclusion criteria for the trial.

The clinical trial is designed to assess the **bioequivalence** of two formulations of amoxicillin and clavulanic acid, specifically a 250 mg/62.5 mg/5 mL powder for oral suspension, compared to Augmentin® Forte of the same dosage, in healthy participants under fed conditions. This is a Phase 2 trial, which is categorized as a bioequivalence study. The trial employs a randomized, double-blind, controlled design to ensure the reliability and validity of the results. The estimated recruitment start date is July 26, 2024, with an anticipated end date of September 14, 2024, indicating a relatively short trial duration.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This visit will involve assessments to confirm the absence of any medical conditions, as the study is conducted in healthy individuals. Following successful screening, participants will be randomized to receive either the test or reference formulation. Subsequent follow-up visits will be scheduled to monitor the participants' health status, adherence to the study protocol, and to collect pharmacokinetic data. The end-of-study visit will conclude the trial, where final assessments will be conducted to ensure participant safety and to gather any remaining data.

The expected length of participant involvement is approximately two months, from the initial screening to the end-of-study visit. Conditions that may lead to early termination from the study include non-compliance with the study protocol, adverse events that compromise participant safety, or withdrawal of consent. The trial is structured to maintain scientific rigor while ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 2 study. The trial is scheduled to begin recruitment on July 26, 2024, with an estimated end date of September 14, 2024. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured timeline to ensure systematic data collection and analysis. The study will adhere to rigorous standards typical of Phase 2 trials, focusing on evaluating the treatment's effectiveness in the target population. The trial's design will incorporate appropriate methodologies to ensure the reliability and validity of the efficacy outcomes.